Kane Biotech enrolls 28 participants for revyve studies

Dr. Robert Huizinga reports KANE BIOTECH COMPLETES ENROLLMENT IN U.S. CASE SERIES STUDIES OF ITS REVYVE ANTIMICROBIAL WOUND GEL AND SPRAY Kane Biotech Inc. has enrolled 28 participants in its revyve anti-microbial wound gel and spray U.S. case series studies, exceeding its 25-participant target. U.S. Food and Drug Administration 510(k) cleared revyve anti-microbial wound gel For the clinical series, Kane engaged wound care and burn specialists in the United States. Data are anticipated to be presented at various medical meetings in 2025 and 2026. "Interest from clinicians and patients in the U.S. case series is encouraging," said Dr. Robert Huizinga, interim chief executive officer. "revyve products can meaningfully improve outcomes for those suffering from challenging wounds and burns." About Kane Biotech Inc. Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. Its revyve anti-microbial wound gel and revyve anti-microbial wound gel spray are U.S. FDA 510(k) cleared. We seek Safe Harbor.